Hikma to take over several assets from Xellia, including a US manufacturing site
Generic drug company Hikma is bolstering its portfolio by acquiring parts of Xellia Pharmaceuticals’ finished dosage form business in the US.
This includes Hikma taking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.